Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3Kδ inhibitor, linperlisib

prnasiaApril 01, 2021

Tag: Yingli Pharma , Follicular lymphoma , linperlisib , PI3Kδ inhibitor

PharmaSources Customer Service